Cooperative Agreement 2150936
Award Date 3/1/22
Completion Date 8/31/25
Dollars Obligated $1.4M
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
East Lansing, MI 48823, USA
Similar Awards
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Phase I Small Business Technology Transfer (STTR) grant awarded $304,438 to Nitro Biosciences Inc. on October 1, 2025. The project aims to develop a novel vaccine platform to engineer vaccines that provide more durable protection against rapidly evolving infectious diseases. The innovation seeks to overcome immune imprinting limitations in current vaccines by directing immune responses toward conserved,...
- This Cooperative Agreement award, provided by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), is funding research and development efforts by Invvax, Inc. to create stable prophylactic antibodies (SPABs) capable of long-term infectious disease prevention. The $996,606 Phase II SBIR grant supports Invvax's work to discover antibody mutations that significantly enhance stability, extending their lifespan from weeks to years....
- This National Science Foundation Project Grant of $255,927 awarded to Invvax, Inc. on March 1, 2022 seeks to develop stable prophylactic antibodies through February 2023. Funded through the NSF Engineering Directorate's CFDA 47.041 program, this Small Business Innovation Research Phase I project will engineer mutations to antibody Fc regions to resist degradation and enhance binding to the neonatal Fc receptor for potentially decades-long duration. Specifically, the awardee will combine known...
- This SBIR Phase I award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $273,550 to Biocognon LLC for the development of a combinatorial platform to discover improved molecular recognition components for use in therapeutic and diagnostic antibodies. The project aims to utilize synthetic biology, next-generation DNA sequencing, and computational biology to efficiently generate and screen libraries of antibody...
- The National Science Foundation (NSF) awarded a $997,689 Cooperative Agreement under its NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Omnicyte LLC, a minority-owned small business in Branford, CT. The funding supports the design and production of a next-generation COVID-19 vaccine that addresses weaknesses of current vaccines, such as reduced booster effectiveness, short-lived efficacy, and side effects. The project aims to develop a vaccine candidate with improved...
- This SBIR Phase I award from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program provides $305,000 to Plexymer, Inc. to develop an AI-powered automation platform to accelerate the formulation of antibody therapeutics. The project aims to reduce the time and materials required to formulate antibody medicines, potentially enabling a transition from hospital infusions to self-administered at-home injections. The AI-driven platform will model and...
- This $304,742 Project Grant award from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program aims to develop a novel low-cost intradermal delivery platform for nucleic acid vaccines. The project will demonstrate the feasibility of delivering "naked" nucleic acid vaccines without the use of lipid nanoparticles, which can be complex and costly to produce. The key technical approach is to leverage a handheld pen device that utilizes...
- This SBIR Phase I project, awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program, is focused on the development of a novel mammalian cell-based nano-biological coating for implantable medical devices. The goal is to address the critical health and economic burden associated with implant-related infections by reducing or eliminating them through the use of this biocompatible and antimicrobial nano-biological coating. The $305,000...
- This STTR Phase I project from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) awarded $305,000 to Immuno Nano Med, Inc. to demonstrate the feasibility of producing a novel room-temperature-stable, dry-powder inhalable influenza vaccine. The project aims to develop an innovative vaccine technology that can provide durable protective immunity through nasal delivery, while eliminating the need for cold chain storage. This would result in...
- This SBIR Phase I project, awarded by the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), aims to develop a method to turn on cancer immunotherapies only at the site of disease. The $275,000 award will support Synsorybio, Inc., a for-profit organization, in creating protein switches that activate immunotherapies in response to disease signals, rather than indiscriminately throughout the body. This approach seeks to improve the...